



Section 1. Patient Information

Patient name (first, MI, last) _____
 DOB _____ Gender F M
 Address _____
 City _____ State _____ ZIP _____

Mobile phone (_____) _____ Preferred # Voicemail
 Alternate phone (_____) _____ Preferred # Voicemail
 Email _____
 Preferred patient language (if not English) _____

Patient Authorization

I have read the Text Messaging Consent in Section 9 and expressly consent to receive text messages by or on behalf of the Program

I have read and agree to the Patient Authorization to Use and Disclose Health Information included in Section 8

Sign 

Patient signature/Legal representative

Date

self

Print name

Relationship to patient

Sign 

Patient signature/Legal representative

Date

self

Print name

Relationship to patient

Section 2. Insurance Information

No insurance (Please fill out Section 7 if you do not have health insurance.)

Please attach copies of front and back of primary medical and prescription cards.

Primary medical insurance name _____
 Insurance phone (_____) _____
 Policy ID # _____ Group # _____
 Policyholder name (first/last) _____
 Relationship to patient _____

Primary Rx insurance name (if different) _____

Secondary insurance card attached

Rx insurance phone (_____) _____

Policy ID # _____ Group # _____

Rx BIN # _____ Rx PCN # _____

Section 3. Prescriber Information

Prescriber name Winston Vaughan
 Prescriber NPI # 1821182973 Group tax ID # _____
 Specialty ENT
 Address 3351 El Camino Real, #200
 City Atherton State CA ZIP 94027

Site/facility name Atherton

Office contact name Kathleen

Office contact email sinusnp@calsinus.com

Phone (650) 399-4630

Fax (650) 366-4930

Section 4. Diagnosis (Complete ONE diagnosis only)

Clinical and Prescription Information (Please attach any office chart notes relevant to therapy.)

Moderate-to-severe asthma with eosinophilic phenotype or oral corticosteroid dependent asthma

ICD-10-CM code(s) J45, J45, Date of diagnosis _____

See the list of potential ICD-10-CM codes on last page Primary Secondary

Patient has moderate-to-severe asthma with an eosinophilic phenotype:

Eosinophil levels (if available) _____ cells/mcL Test date _____

Patient has moderate-to-severe asthma with oral corticosteroid dependent asthma

Pre-bronchodilator FEV₁ <80% (adults) or <90% (aged 12–17 years)? Yes No

Atopic comorbidities (specify) _____

Number of severe exacerbations in the past 12 months _____

Chronic rhinosinusitis with nasal polyposis

ICD-10-CM code(s) J33.0, J33, Date of diagnosis _____

See the list of potential ICD-10-CM codes on last page Primary Secondary

Diagnosis confirmed by Endoscopy CT scan

Patient has had prior sinus surgery Yes No

If yes, indicate

Date(s) and type(s) of sinus surgery _____

Atopic comorbidities (specify) _____

Please see full indications on next page. CT=computerized tomography; FEV₁=forced expiratory volume in 1 second; ICD-10-CM=International Classification of Diseases, Tenth Revision, Clinical Modification.

Section 5. Prescription Information

My preferred specialty pharmacy is _____
 Phone (_____) _____ Fax (_____) _____
 Sample product: No sample provided Sample provided on _____

I have already sent this prescription to the specialty pharmacy. By checking the box, I acknowledge DUPIXENT MyWay® will not conduct a benefits verification. The specialty pharmacy is responsible for securing coverage on my patient's behalf.

Moderate-to-severe asthma with eosinophilic phenotype or oral corticosteroid dependent asthma

Rx: DUPIXENT® (dupilumab), prefilled syringe, 2 pack

Initial dose: 400 mg/2.28 mL SIG: 2 injections subcutaneously on Day 1

Maintenance dose: 200 mg/1.14 mL SIG: 1 injection every 2 weeks starting on Day 15

Qty: 2 pk Refills _____

Initial dose: 600 mg/4 mL SIG: 2 injections subcutaneously on Day 1

Maintenance dose: 300 mg/2 mL SIG: 1 injection every 2 weeks starting on Day 15

Qty: 2 pk Refills _____

Maintenance: Other

Dose _____ SIG: _____

Frequency _____ Qty _____ Refills _____

Known drug allergies: _____

Chronic rhinosinusitis with nasal polyposis

Rx: DUPIXENT® (dupilumab), prefilled syringe, 2 pack

Dose: 300 mg/2 mL SIG: 1 injection every 2 weeks
 Qty: 2 pk Refills 12

Other

Dose _____ SIG: _____

Frequency _____ Qty _____ Refills _____

Known drug allergies: _____

Sign 

Prescriber signature (No stamps) Dispense as written

Date

OR

Sign 

Prescriber signature (No stamps) Substitution permitted

Date

Collaborating MD name _____ NPI # _____
 (Nurse practitioner/physician assistant)

My signature certifies that the person named on this form is my patient; the information provided on this application, to the best of my knowledge, is complete and accurate; and that therapy with DUPIXENT is medically necessary. I understand that my patient's information provided to Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (the "Alliance") for the use of DUPIXENT MyWay® solely to verify my patient's insurance coverage, to assess, if applicable, my patient's eligibility for patient assistance and other support programs; and to otherwise administer DUPIXENT MyWay for the patient. I request DUPIXENT MyWay to conduct a benefits investigation for my patient and authorize DUPIXENT MyWay to act on my behalf for the limited purpose of transmitting this prescription to the appropriate pharmacy designated by the patient per their benefit plan provided that, if this prescription is not so designated, DUPIXENT MyWay is authorized to transmit this prescription to a network pharmacy it selects or to the pharmacy otherwise indicated. I understand that free product is not contingent on any purchase obligations. I also understand that no free product may be submitted for reimbursement to any payer, including Medicare and Medicaid; and no free product may be sold, traded, or distributed for sale. I consent to DUPIXENT MyWay contacting me by fax, mail, or email to provide additional information about DUPIXENT injection or DUPIXENT MyWay, and that DUPIXENT MyWay may revise, change, or terminate any program services at any time without notice to me.

If you are a New York prescriber, please use an original New York State prescription form. The prescriber is to comply with his/her state-specific prescription requirements, such as e-prescribing, state-specific prescription form, fax language, etc. Non-compliance with state-specific requirements could result in outreach to the prescriber.



Patient Name

DOB

Prescriber Name Winston Vaughan

NPI# 1821182973

Section 8. Authorization to Use and Disclose Health Information

Please read the following carefully, then date and sign where indicated in Section 1 on page 1

I authorize my healthcare providers and staff, my health insurer, health plan or programs that provide me healthcare benefits (together, "Health Insurers"), and any specialty pharmacies that dispense my medication to disclose to Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (together, the "Alliance") health information about me, including information related to my medical condition and treatment, health insurance coverage and claims, and prescription (including fill/refill information) related to my prescription for DUPIXENT® (dupilumab) therapy ("My Information"). I understand the disclosure to the Alliance will be for the purposes of enrolling me in, and providing certain services through the "DUPIXENT MyWay® Program," including:

- to determine if I am eligible to participate in DUPIXENT MyWay coverage assistance programs, patient assistance programs, or other support programs
- to investigate my health insurance coverage for DUPIXENT injection
- to obtain prior authorization for coverage
- to assist with appeals of denied claims for coverage
- for the operation and administration of the DUPIXENT MyWay Program
- to refer me to, or to determine my eligibility for, other programs, foundations, or alternative sources of funding or coverage that may be available to provide assistance to me with the costs of my medication

I authorize and agree that the Alliance's field level employees may have access to My Information in order to assist the Alliance in providing support services in connection with the DUPIXENT MyWay Program.

I understand and agree that my healthcare providers, Health Insurers, and specialty pharmacy(ies) may receive remuneration from the Alliance in exchange for disclosing My Information to the Alliance and/or for providing me with support services in connection with the DUPIXENT MyWay Program.

Once My Information has been disclosed to the Alliance, I understand that federal privacy laws may no longer protect it from further disclosure. However, I also understand the Alliance will protect My Information by using and disclosing it only for the purposes allowed by me in this Authorization or as otherwise allowed by law.

I understand that I do not have to sign this Authorization. A decision by me not to sign this Authorization will not affect my ability to obtain medical treatment, insurance coverage, access to health benefits or Alliance medications. However, if I do not sign this Authorization, I understand that I will not be able to participate in the DUPIXENT MyWay Program.

I understand that this Authorization expires 18 months from the date support is last provided under the Program, or until my local state law requires expiration, subject to applicable law, unless and until I withdraw (take back) this Authorization before then, or as otherwise required by law. Further, I understand that I may withdraw this Authorization at any time by mailing or faxing a written request to DUPIXENT MyWay at 1800 Innovation Point, Fort Mill, SC 29715; Fax: 1-844-387-9370. Withdrawal of this Authorization will end my participation in the DUPIXENT MyWay Program and will not affect any disclosure of My Information based on this Authorization made before my request is received and processed by my healthcare providers and staff, my Health Insurers, and specialty pharmacy(ies).

I understand that I may request a copy of this Authorization.



Patient Name

Prescriber Name Winston Vaughan

DOB

NPI# 1821182973

Section 9. Patient Certifications

Please read the following carefully, then date and sign where indicated in Section 1 on page 1

I am enrolling in the DUPIXENT MyWay® Program (the “Program”) and authorize Regeneron Pharmaceuticals, Inc., Sanofi US, and their affiliates and agents (together the “Alliance”) to provide me services under the Program, as described in the Program Enrollment Form and as may be added in the future. Such services include medication and adherence communications and support, medication dispensing support, coverage and financial assistance support, disease and medication education, injection training, and other support services (the “Services”).

I agree to my enrollment in the DUPIXENT MyWay Copay Card Program if confirmed as eligible, understand that Copay Card information will be sent to my designated specialty pharmacy along with my prescription, and any assistance with my applicable cost-sharing or copayment for DUPIXENT® (dupilumab) injection will be made in accordance with the Program terms and conditions.

If I am completing Section 7, I confirm my agreement with the conditions set forth in Section 7, and certify that my household income is true and accurate to the best of my knowledge. I authorize the Alliance to contact me by mail, telephone, or e-mail, or, if I indicate my agreement and consent on page 1, by text,^a with information about the Program, disease state and products, promotions, services, and research studies, and to ask my opinion about such information and topics, including market research and disease-related surveys. I further authorize the Alliance to de-identify my health information and use it in performing research, including linkage with other de-identified information the Alliance receives from other sources, education, business analytics, marketing studies, or for other commercial purposes. I understand that members of the Alliance may share identifiable health information with one another in order to de-identify it for these purposes and as needed to perform the Services or to send the communications listed above (the “Communications”). I understand and agree that the Alliance may use my health information for these purposes and may share my health information with my doctors, specialty pharmacies, and insurers. I understand that I may be contacted by the Alliance in the event that I report an adverse event.

I understand that I do not have to enroll in the Program or receive the Communications, and that I can still receive DUPIXENT injection, as prescribed by my physician. I may opt out of receiving Communications, individual support services offered by the Program, including the DUPIXENT MyWay Copay Card, or opt out of the Program entirely at any time by notifying a Program representative by telephone at 1-844-387-4936 or by sending a letter to DUPIXENT MyWay, 1800 Innovation Point, Fort Mill, SC 29715. I also understand that the Services may be revised, changed, or terminated at any time.

Continuation in the DUPIXENT MyWay Patient Assistance Program is conditioned upon timely verification of income. In addition, I agree to notify DUPIXENT MyWay if my insurance situation changes.

Text Messaging Consent:

^aI acknowledge that by checking the Text Messaging Consent box on page 1, I expressly consent to receive text messages from or on behalf of the Program at the mobile telephone number(s) that I provide.

I confirm that I am the subscriber for the mobile telephone number(s) provided, and I agree to notify the Alliance promptly if any of my number(s) change in the future. I understand that my wireless service provider’s message and data rates may apply. I understand that I can opt out of future text messages at any time by texting SMSSTOP to 39771 from my mobile phone, and that I can get help for text messages by texting SMSHELP to 39771. I also understand that additional text messaging terms and conditions may be provided to me in the future as part of an opt-in confirmation text message. Message and data rates may apply.

I understand that my consent is not required as a condition of purchasing any goods or services from Regeneron Pharmaceuticals, Inc., Sanofi US, or their affiliates.

You may keep a copy of this form for your records.

Complete entire form and fax **the first 4 PAGES** to DUPIXENT MyWay at 1-844-387-9370.

SANOFI GENZYME  **REGENERON**

Please click here for the full Prescribing Information.

© 2019 Sanofi and Regeneron Pharmaceuticals, Inc.

All Rights Reserved.

06/2019

US-DUP-1265a

DUPIXENT®
(dupilumab) Injection
200mg • 300mg

**Moderate-to-severe asthma with eosinophilic phenotype or oral corticosteroid dependent asthma**

- **J45.4** (Moderate persistent asthma)
- **J45.40** (Moderate persistent asthma, uncomplicated)
- **J45.41** (Moderate persistent asthma with [acute] exacerbation)
- **J45.5** (Severe persistent asthma)
- **J45.50** (Severe persistent asthma, uncomplicated)
- **J45.51** (Severe persistent asthma with [acute] exacerbation)
- **J45.9** (Other and unspecified asthma)
- **J45.90** (Unspecified asthma)
- **J45.901** (Unspecified asthma with [acute] exacerbation)

**Chronic rhinosinusitis with nasal polyposis**

- **J33** (Nasal polyp)
- **J33.0** (Polyp of the nasal cavity)
- **J33.1** (Polypoid sinus degeneration)
- **J33.8** (Other polyp of sinus)
- **J33.9** (Nasal polyp, unspecified)

This coding information is provided for informational purposes only and is subject to change. These codes may not apply to all patients or to all health plans; providers must exercise independent judgment when selecting codes and submit claims that accurately reflect the diagnoses of a specific patient.